Recent Articles The Return of 503B Compounding of GLP-1 Medications Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has created both clinical October 23, 2025 FDA Issues Import Alert on GLP-1s Following Launch of Green List On September 19, 2025, the FDA issued Import Alert 66-80, which authorizes field staff to detain without physical examination shipments of GLP-1 active pharmaceutical ingredients October 1, 2025 Thea GLP-1 Crossroads: What Pharmacies Must Know About Compliance, Coverage, and the Future of Access The surge of GLP-1 medications, from semaglutide products such as Ozempic and Wegovy to new therapies in the pipeline, has created one of September 4, 2025 Recent Webinars Navigating GLP-1 Compounding Webinar Series Stay ahead of the curve with our webinar series navigating the evolving regulatory landscape for GLP-1 compounding
How does GHK-Cu relate to collagen and ECM remodeling
Statement of ethics The study was approved by the West Midlands - Solihull Research Ethics Committee (17/WM/0179) and all subjects provided written informed consent according to the Declaration of Helsinki principles
Optimizing your tirzepatide investment Whether you use Afterpay, Klarna, CareCredit, or pay cash, getting the most value from your tirzepatide investment goes beyond payment method
It's not covered by standard 503A/503B compounding frameworks applicable to shortage drugs
This returns the body to its previous state of defending a higher weight or set point, making weight regain highly likely without strong behavioral changes
